The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

NCT01513733 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: tasquinimod
DRUG: tasquinimod 0.25 mg; 0.5 mg
DRUG: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg

Sponsor

Andrew J. Armstrong, MD